SEC Filings

Form S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Document Outline
Entire Document (9563.4 KB)
Subdocument 1 - S-1 - S-1
Page 1 - As filed with the Securities and Exchange Commission on August 12, 2014
Page 2 - Preliminary Prospectus
Page 3 - TABLE OF CONTENTS
Page 4 - PROSPECTUS SUMMARY
Page 5 - Our Most Advanced Product Candidates
Page 6 - VTP-43742
Page 7 - Our Collaborations
Page 8 - Intellectual Property
Page 9 - Corporate Information
Page 10 - The Offering
Page 11 - N/A
Page 12 - SUMMARY FINANCIAL DATA
Page 13 - N/A
Page 14 - RISK FACTORS
Page 15 - We will require substantial additional financing to achieve our goals, and a failure to obtain this
Page 16 - Raising additional capital may cause dilution to our existing stockholders, restrict our operations
Page 17 - Our ability to use net operating loss and tax credit carryforwards and certain built-in losses to re
Page 18 - Risks Related to the Clinical Development and Regulatory Approval of Our Product Candidates
Page 19 - Clinical failure may occur at any stage of clinical development, and because our product candidates
Page 20 - If we or our partners fail to obtain regulatory approval in jurisdictions outside the United States,
Page 21 - We and BI rely on third parties to conduct preclinical studies and clinical trials for our product c
Page 22 - We intend to rely on third-party manufacturers, including BI with respect to VTP-34072 and VTP-37948
Page 23 - We may not be successful in establishing and maintaining additional strategic partnerships, which co
Page 24 - N/A
Page 25 - Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecut
Page 26 - Third-party claims of intellectual property infringement or misappropriation may prevent or delay ou
Page 27 - We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, wh
Page 28 - We may need to license certain intellectual property from third parties, and such licenses may not b
Page 29 - Our reliance on third parties requires us to share our trade secrets, which increases the possibilit
Page 30 - If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent terms and o
Page 31 - Coverage and reimbursement may be limited or unavailable in certain market segments for our product
Page 32 - The impact of recent healthcare reform legislation and other changes in the healthcare industry and
Page 33 - We face substantial competition, which may result in others discovering, developing or commercializi
Page 34 - Our product candidates may cause undesirable side effects or have other properties that delay or pre
Page 35 - Risks Related to Our Business and Industry
Page 36 - Our employees, independent contractors, principal investigators, CROs, consultants, commercial partn
Page 37 - N/A
Page 38 - We may encounter difficulties in managing our growth and expanding our operations successfully.
Page 39 - If product liability lawsuits are brought against us, we may incur substantial liabilities and may b
Page 40 - Our internal computer systems, or those of our development partners, third-party clinical research o
Page 41 - The trading price of the shares of our common stock could be highly volatile, and purchasers of our
Page 42 - If securities or industry analysts do not publish research or reports or publish unfavorable researc
Page 43 - Sales of a substantial number of shares of our common stock by our existing stockholders in the publ
Page 44 - We will incur significant increased costs as a result of operating as a public company, and our mana
Page 45 - If we fail to maintain proper and effective internal control over financial reporting in the future,
Page 46 - Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition o
Page 47 - INFORMATION REGARDING FORWARD-LOOKING STATEMENTS
Page 48 - INDUSTRY AND MARKET DATA
Page 49 - USE OF PROCEEDS
Page 50 - DIVIDEND POLICY
Page 51 - CAPITALIZATION
Page 52 - N/A
Page 53 - DILUTION
Page 54 - N/A
Page 55 - SELECTED FINANCIAL DATA
Page 56 - N/A
Page 57 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF
Page 58 - Strategic Partnerships
Page 59 - B-site Amyloid Precursor Protein-Cleaving Enzyme Inhibitors with BI
Page 60 - Financial Operations Overview
Page 61 - Milestone Revenue
Page 62 - N/A
Page 63 - RORgt
Page 64 - Contour and Technology Development
Page 65 - Revenue Recognition
Page 66 - Accrued Clinical and Preclinical Expenses
Page 67 - Stock-Based Compensation
Page 68 - Valuation of Privately-Held-Company Equity Securities Issued as Compensation
Page 69 - Results of Operations
Page 70 - Collaborative Revenues.
Page 71 - Research and Development.
Page 72 - Cash Flows
Page 73 - Comparison of Years Ended December 31, 2013 and 2012
Page 74 - Plan of Operation
Page 75 - Contractual Obligations and Commitments
Page 76 - Recently Adopted Accounting Standards
Page 77 - BUSINESS
Page 78 - N/A
Page 79 - in vivo
Page 80 - Our Strategy
Page 81 - Continue investing in technology, people and intellectual property.
Page 82 - Cortisol in Metabolic Disease
Page 83 - Market Opportunity
Page 84 - Preclinical Data
Page 85 - VTP-37948 Targeting b-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE) for Alzheimer's Diseas
Page 86 - BACE as a Target in Alzheimer's Disease
Page 87 - Market Opportunity
Page 88 - Figure 5: Rats brain tissue assayed for levels of Ab and concentrations of VTP-37948. The various sy
Page 89 - IL-17 and Th17 Cells in Autoimmunity
Page 90 - RORgt as a Target in Autoimmunity
Page 91 - Market Opportunity
Page 92 - Human Whole Blood Assay
Page 93 - Left
Page 94 - Development Plans
Page 95 - Inflammation in ACS
Page 96 - Market Opportunity
Page 97 - ABCA1 mRNA in Human Skin Fibroblasts
Page 98 - Figure 17: Cynomolgus monkeys were dosed once-a-day for 14 days with VTP-38443. Levels of mRNA for A
Page 99 - Development Plans
Page 100 - Figure 19: Depiction of the composition and architecture of the epidermis.
Page 101 - Preclinical Data
Page 102 - Figure 21: VTP-38543 induced genes critical for lipid transport and lipid synthesis in skin.
Page 103 - Inhibition of IL-6 Secretion by THP-1 Macrophages
Page 104 - Immuno-Oncology Program
Page 105 - Contour Discovery Process
Page 106 - de novo
Page 107 - Figure 27: Time to develop a novel chemistry solution and achieve animal proof-of-concept.
Page 108 - Collaborations
Page 109 - BACE
Page 110 - Intellectual Property
Page 111 - LXRb Acute Coronary Syndrome:
Page 112 - Manufacturing
Page 113 - Commercialization
Page 114 - Phase 1.
Page 115 - N/A
Page 116 - Post-approval Requirements
Page 117 - Regulation Outside of the United States
Page 118 - N/A
Page 119 - Coverage and Reimbursement
Page 120 - Employees
Page 121 - Property and facilities
Page 122 - MANAGEMENT
Page 123 - Peter Barrett, Ph.D.
Page 124 - Charles W. Newhall, III
Page 125 - Code of Business Conduct and Ethics
Page 126 - Audit Committee
Page 127 - Compensation Committee Interlocks and Insider Participation
Page 128 - N/A
Page 129 - EXECUTIVE COMPENSATION
Page 130 - Equity Compensation
Page 131 - Outstanding Equity Awards as of December 31, 2013
Page 132 - N/A
Page 133 - Severance Benefits
Page 134 - Retirement Benefits
Page 135 - Letter Agreement with New Chief Business Officer
Page 136 - Administration.
Page 137 - Performance Cash Awards.
Page 138 - Changes in Capitalization.
Page 139 - Administration.
Page 140 - Changes in Capitalization.
Page 141 - Changes in Capitalization.
Page 142 - Eligibility.
Page 143 - 2014 Employee Stock Purchase Plan
Page 144 - CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Page 145 - Right of First Refusal and Co-sale Agreement
Page 146 - PRINCIPAL STOCKHOLDERS
Page 147 - N/A
Page 148 - N/A
Page 149 - DESCRIPTION OF CAPITAL STOCK
Page 150 - Restricted Stock Units
Page 151 - Certificate of Incorporation and Bylaws
Page 152 - Limitation of Liability and Indemnification Matters
Page 153 - SHARES ELIGIBLE FOR FUTURE SALE
Page 154 - Rule 701
Page 155 - MATERIAL UNITED STATES TAX CONSIDERATIONS TO NON-U.S. HOLDERS
Page 156 - Distributions on Our Common Stock
Page 157 - U.S. Federal Estate Tax
Page 158 - N/A
Page 159 - UNDERWRITING
Page 160 - Commissions and Discounts
Page 161 - N/A
Page 162 - NASDAQ Market Listing
Page 163 - Discretionary Sales
Page 164 - Notice to Residents of the United Kingdom
Page 165 - Notice to Residents of the Netherlands
Page 166 - N/A
Page 167 - LEGAL MATTERS
Page 168 - VITAE PHARMACEUTICALS, INC.
Page 169 - Report of Independent Registered Public Accounting Firm
Page 170 - Balance Sheets
Page 171 - Statements of Operations
Page 172 - Statements of Comprehensive Income
Page 173 - Vitae Pharmaceuticals, Inc.
Page 174 - Statements of Cash Flows
Page 175 - 1. Organization
Page 176 - Notes to the Financial Statements (Continued)
Page 177 - Notes to the Financial Statements (Continued)
Page 178 - Notes to the Financial Statements (Continued)
Page 179 - Notes to the Financial Statements (Continued)
Page 180 - Notes to the Financial Statements (Continued)
Page 181 - Notes to the Financial Statements (Continued)
Page 182 - Notes to the Financial Statements (Continued)
Page 183 - Notes to the Financial Statements (Continued)
Page 184 - Notes to the Financial Statements (Continued)
Page 185 - Notes to the Financial Statements (Continued)
Page 186 - Notes to the Financial Statements (Continued)
Page 187 - Notes to the Financial Statements (Continued)
Page 188 - Notes to the Financial Statements (Continued)
Page 189 - Notes to the Financial Statements (Continued)
Page 190 - Notes to the Financial Statements (Continued)
Page 191 - Notes to the Financial Statements (Continued)
Page 192 - Notes to the Financial Statements (Continued)
Page 193 - Notes to the Financial Statements (Continued)
Page 194 - Notes to the Financial Statements (Continued)
Page 195 - Notes to the Financial Statements (Continued)
Page 196 - Notes to the Financial Statements (Continued)
Page 197 - Notes to the Financial Statements (Continued)
Page 198 - Notes to the Financial Statements (Continued)
Page 199 - Notes to the Financial Statements (Continued)
Page 200 - Condensed Balance Sheets
Page 201 - Unaudited Condensed Statements of Operations
Page 202 - Unaudited Condensed Statements of Comprehensive Loss
Page 203 - Unaudited Condensed Statements of Cash Flows
Page 204 - Notes to Unaudited Condensed Financial Statements
Page 205 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 206 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 207 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 208 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 209 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 210 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 211 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 212 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 213 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 214 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 215 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 216 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 217 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 218 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 219 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 220 - Shares
Page 221 - PART II
Page 222 - Item 15. Recent Sales of Unregistered Securities
Page 223 - Item 16. Exhibits and Financial Statement Schedules
Page 224 - provided
Page 225 - SIGNATURES
Page 226 - N/A
Page 227 - EXHIBIT INDEX
Page 228 - N/A
Subdocument 2 - EX-3.1 - EX-3.1
Page 1 - Exhibit 3.1
Page 2 - Delaware
Page 3 - CERTIFICATE OF INCORPORATION
Page 4 - N/A
Page 5 - [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
Page 6 - IN WITNESS WHEREOF,
Page 7 - ARTICLE II
Page 8 - Liquidation Preference
Page 9 - Redemption.
Page 10 - provided, however,
Page 11 - N/A
Page 12 - N/A
Page 13 - Other Conversion Price Adjustments, Stock Splits and Combinations.
Page 14 - Other Distributions.
Page 15 - No Fractional Shares and Certificate as to Adjustments.
Page 16 - provided
Page 17 - Voting Rights
Page 18 - ARTICLE X
Page 19 - N/A
Page 20 - CERTIFICATE OF OWNERSHIP AND MERGER
Page 21 - EXHIBIT A
Page 22 - Merger of Initio Pharmaceuticals, Inc., a Delaware Corporation, into Concurrent Pharmaceuticals, Inc
Page 23 - RESOLVED FURTHER,
Page 24 - ARTICLE II
Page 25 - Liquidation Preference
Page 26 - N/A
Page 27 - Redemption
Page 28 - Conversion Price Adjustments for Certain Dilutive Issuances
Page 29 - N/A
Page 30 - N/A
Page 31 - Other Conversion Price Adjustments, Stock Splits and Combinations.
Page 32 - Recapitalizations
Page 33 - Protective Provisions
Page 34 - provided
Page 35 - ARTICLE V
Page 36 - ARTICLE X
Page 37 - RESTATED CERTIFICATE OF INCORPORATION
Page 38 - ARTICLE II
Page 39 - Liquidation Preference
Page 40 - N/A
Page 41 - Redemption
Page 42 - Conversion Price Adjustments for Certain Dilutive Issuances
Page 43 - N/A
Page 44 - N/A
Page 45 - Other Conversion Price Adjustments, Stock Splits and Combinations
Page 46 - Recapitalizations
Page 47 - Protective Provisions
Page 48 - provided
Page 49 - ARTICLE V
Page 50 - ARTICLE X
Page 51 - CERTIFICATE OF AMENDMENT
Page 52 - AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
Page 53 - ARTICLE II
Page 54 - Liquidation Preference.
Page 55 - N/A
Page 56 - N/A
Page 57 - Redemption.
Page 58 - Conversion Price Adjustments for Certain Dilutive Issuances
Page 59 - N/A
Page 60 - N/A
Page 61 - Other Conversion Price Adjustments, Stock Splits and Combinations
Page 62 - Notices
Page 63 - Protective Provisions
Page 64 - Status of Converted Stock
Page 65 - ARTICLE VI
Page 66 - ARTICLE XII
Page 67 - AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
Page 68 - ARTICLE II
Page 69 - Liquidation Preference
Page 70 - N/A
Page 71 - N/A
Page 72 - Redemption
Page 73 - Conversion Price Adjustments for Certain Dilutive Issuances
Page 74 - N/A
Page 75 - N/A
Page 76 - Other Conversion Price Adjustments, Stock Splits and Combinations
Page 77 - Notices
Page 78 - Protective Provisions
Page 79 - Status of Converted Stock
Page 80 - ARTICLE VI
Page 81 - ARTICLE XII
Page 82 - AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
Page 83 - ARTICLE II
Page 84 - Liquidation Preference
Page 85 - N/A
Page 86 - N/A
Page 87 - Redemption
Page 88 - Conversion Price Adjustments for Certain Dilutive Issuances
Page 89 - N/A
Page 90 - N/A
Page 91 - Other Conversion Price Adjustments, Stock Splits and Combinations.
Page 92 - Notices
Page 93 - Protective Provisions
Page 94 - provided
Page 95 - Voting Rights
Page 96 - ARTICLE X
Page 97 - N/A
Page 98 - CERTIFICATE OF AMENDMENT
Page 99 - [Remainder of Page Intentionally Left Blank]
Page 100 - AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
Page 101 - ARTICLE II
Page 102 - N/A
Page 103 - Liquidation Preference
Page 104 - N/A
Page 105 - Redemption
Page 106 - Mechanics of Conversion
Page 107 - Other Distributions
Page 108 - Reservation of Stock Issuable Upon Conversion
Page 109 - Voting Rights
Page 110 - Common Stock
Page 111 - ARTICLE VIII
Page 112 - ARTICLE XII
Page 113 - CERTIFICATE OF AMENDMENT
Page 114 - [Remainder of Page Intentionally Left Blank]
Page 115 - N/A
Page 116 - CERTIFICATE OF AMENDMENT
Page 117 - [Remainder of Page Intentionally Left Blank]
Page 118 - N/A
Page 119 - CERTIFICATE OF AMENDMENT
Page 120 - [Remainder of Page Intentionally Left Blank]
Page 121 - IN WITNESS WHEREOF, Vitae Pharmaceuticals, Inc. has caused this Certificate of Amendment to be signe
Subdocument 3 - EX-3.3 - EX-3.3
Page 1 - Exhibit 3.3
Page 2 - TABLE OF CONTENTS
Page 3 - BYLAWS
Page 4 - N/A
Page 5 - ARTICLE III
Page 6 - MEETINGS OF THE BOARD OF DIRECTORS
Page 7 - COMMITTEES OF DIRECTORS
Page 8 - COMPENSATION OF DIRECTORS
Page 9 - ARTICLE V
Page 10 - THE PRESIDENT AND VICE-PRESIDENTS
Page 11 - LOST CERTIFICATES
Page 12 - REGISTERED STOCKHOLDERS
Page 13 - N/A
Page 14 - ARTICLE VIII
Page 15 - CERTIFICATE OF SECRETARY OF
Subdocument 4 - EX-3.4 - EX-3.4
Page 1 - Exhibit 3.4
Page 2 - TABLE OF CONTENTS
Page 3 - N/A
Page 4 - ARTICLE I
Page 5 - Voting List
Page 6 - Voting and Proxies
Page 7 - provided
Page 8 - Exchange Act
Page 9 - N/A
Page 10 - provided
Page 11 - provided
Page 12 - Conduct of Meetings
Page 13 - ARTICLE II
Page 14 - Action at Meeting
Page 15 - Meetings by Conference Communications Equipment
Page 16 - ARTICLE III
Page 17 - Chief Financial Officer
Page 18 - ARTICLE IV
Page 19 - Lost, Stolen or Destroyed Certificates
Page 20 - Electronic Transmission
Page 21 - Authorization of Indemnification
Page 22 - Expenses Payable in Advance
Page 23 - Survival of Indemnification and Advancement of Expenses
Page 24 - Contract Rights
Subdocument 5 - EX-4.2 - EX-4.2
Page 1 - Exhibit 4.2
Page 2 - TABLE OF CONTENTS
Page 3 - N/A
Page 4 - VITAE PHARMACEUTICALS, INC.
Page 5 - Registration Rights
Page 6 - Request for Registration
Page 7 - Company Registration
Page 8 - Underwriting Requirements
Page 9 - Obligations of the Company
Page 10 - Information from Holder
Page 11 - N/A
Page 12 - Reports Under Securities Exchange Act of 1934
Page 13 - provided
Page 14 - Termination of Registration Rights
Page 15 - Inspection
Page 16 - N/A
Page 17 - N/A
Page 18 - Board of Directors
Page 19 - Required Notices
Page 20 - Key Person Insurance
Page 21 - Tax Disclosure
Page 22 - Miscellaneous
Page 23 - Entire Agreement; Amendments and Waivers
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Page 29 - N/A
Page 30 - N/A
Page 31 - SCHEDULE A
Page 32 - SCHEDULE B
Subdocument 6 - EX-10.1 - EX-10.1
Page 1 - Exhibit 10.1
Page 2 - Expenses
Page 3 - Agreement to Serve
Page 4 - Partial Indemnification
Page 5 - Application for Enforcement
Page 6 - Exceptions
Page 7 - Securities Act Liabilities
Page 8 - Term
Page 9 - Governing Law
Page 10 - IN WITNESS WHEREOF,
Subdocument 7 - EX-10.2 - EX-10.2
Page 1 - Exhibit 10.2
Page 2 - TABLE OF CONTENTS
Page 3 - N/A
Page 4 - VITAE PHARMACEUTICALS, INC. 2001 STOCK PLAN
Page 5 - SECTION 4. STOCK SUBJECT TO PLAN
Page 6 - SECTION 6. TERMS AND CONDITIONS OF OPTIONS
Page 7 - (k)
Page 8 - (e)
Page 9 - (c)
Page 10 - SECTION 10. NO RETENTION RIGHTS
Page 11 - Code
Page 12 - Outside Director
Page 13 - Section 13 of the Stock Option Agreement includes important acknowledgements of the Optionee
Page 14 - SECTION 2.
Page 15 - SECTION 5.
Page 16 - Death of the Optionee
Page 17 - SECTION 7.
Page 18 - SECTION 10.
Page 19 - Legends
Page 20 - SECTION 12.
Page 21 - SECTION 14.
Page 22 - ISO
Page 23 - Transferee
Subdocument 8 - EX-10.3 - EX-10.3
Page 1 - Exhibit 10.3
Page 2 - TABLE OF CONTENTS
Page 3 - N/A
Page 4 - CONCURRENT PHARMACEUTICALS, INC. 2004 STOCK PLAN
Page 5 - SECTION 4. STOCK SUBJECT TO PLAN.
Page 6 - SECTION 6. TERMS AND CONDITIONS OF OPTIONS.
Page 7 - Accelerated Exercisability.
Page 8 - SECTION 7. PAYMENT FOR SHARES.
Page 9 - SECTION 8. ADJUSTMENT OF SHARES.
Page 10 - SECTION 9. SECURITIES LAW REQUIREMENTS.
Page 11 - SECTION 12. DEFINITIONS.
Page 12 - Company
Page 13 - Service
Page 14 - UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED
Page 15 - SECTION 3.
Page 16 - Exercise/Pledge
Page 17 - Leaves of Absence
Page 18 - Transfer of Shares
Page 19 - Investment Intent at Grant
Page 20 - Removal of Legends
Page 21 - Choice of Law
Page 22 - Disability
Page 23 - Service
Subdocument 9 - EX-10.4 - EX-10.4
Page 1 - Exhibit 10.4
Page 2 - TABLE OF CONTENTS
Page 3 - N/A
Page 4 - VITAE PHARMACEUTICALS, INC. 2013 STOCK PLAN
Page 5 - (b)
Page 6 - (b)
Page 7 - (e)
Page 8 - (i)
Page 9 - SECTION 7.
Page 10 - SECTION 8.
Page 11 - (c)
Page 12 - (e)
Page 13 - SECTION 10. PRE-EXERCISE INFORMATION REQUIREMENT
Page 14 - (f)
Page 15 - SECTION 12. DURATION AND AMENDMENTS; STOCKHOLDER APPROVAL
Page 16 - Company
Page 17 - NSO
Page 18 - Stock
Page 19 - EXHIBIT A
Page 20 - THE OPTION GRANTED PURSUANT TO THIS AGREEMENT AND THE SHARES ISSUABLE UPON THE EXERCISE THEREOF HAVE
Page 21 - Stockholder Approval
Page 22 - Surrender of Stock
Page 23 - Extension of Post-Termination Exercise Periods
Page 24 - SECTION 7.
Page 25 - Termination of Right of First Refusal
Page 26 - Investment Intent at Grant
Page 27 - Removal of Legends
Page 28 - Notice
Page 29 - Electronic Delivery of Documents
Page 30 - Termination of Service
Page 31 - Company
Page 32 - Plan
Page 33 - VITAE PHARMACEUTICALS, INC. 2013 STOCK PLAN
Page 34 - Expiration of RSUs
Page 35 - SECTION 4.
Page 36 - Section 409A
Page 37 - SECTION 6.
Page 38 - Termination of Right of First Refusal
Page 39 - Legends
Page 40 - Removal of Legends
Page 41 - Effect on Other Employee Benefit Plans
Page 42 - Data
Page 43 - Immediate Family
Page 44 - Transfer Notice
Subdocument 10 - EX-10.6 - EX-10.6
Page 1 - Exhibit 10.6
Page 2 - TABLE OF CONTENTS
Page 3 - N/A
Page 4 - N/A
Page 5 - RESEARCH COLLABORATION AND LICENSE AGREEMENT
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - Handelsgesetzbuch
Page 14 - de jure
Page 15 - N/A
Page 16 - 2. LICENSE GRANTS, OWNERSHIP AND EXCLUSIVITY
Page 17 - Licenses to Vitae
Page 18 - Trademarks
Page 19 - Committees
Page 20 - Meetings
Page 21 - Decision-Making
Page 22 - Responsibilities
Page 23 - Joint Development Committee
Page 24 - Research Plan
Page 25 - Reports
Page 26 - Development Candidate Selection
Page 27 - 5. DEVELOPMENT OF PRODUCTS
Page 28 - Obligation to Notify Promptly of Delays
Page 29 - Responsibility for Development
Page 30 - Reports
Page 31 - Recalls or Corrective Action
Page 32 - Execution Payment
Page 33 - Commercialization Milestones
Page 34 - bona fide
Page 35 - Royalty Adjustments
Page 36 - Equity Investment
Page 37 - 10. CONFIDENTIAL INFORMATION
Page 38 - Permitted Disclosure and Use
Page 39 - 11. REPRESENTATIONS AND WARRANTIES
Page 40 - Vitae Representations and Warranties
Page 41 - Disclaimer of Warranty
Page 42 - Insurance
Page 43 - Prosecution and Maintenance of Patents
Page 44 - Selection of Patent Counsel
Page 45 - Patent Prosecution and Maintenance Expenses
Page 46 - Execution of Documents by Agents
Page 47 - Patent Infringement
Page 48 - Notice of Certification
Page 49 - Settlement
Page 50 - Effects of Termination; Terminated Products
Page 51 - Terminations Other Than Material Breach by Vitae
Page 52 - N/A
Page 53 - Change of Control
Page 54 - Bankruptcy under U.S. or German Law
Page 55 - Public Announcements
Page 56 - Registration of This Agreement
Page 57 - Governing Law
Page 58 - Severability
Page 59 - N/A
Page 60 - EXHIBIT 1
Page 61 - EXHIBIT 2
Page 62 - EXHIBIT 4
Page 63 - EXHIBIT 6
Page 64 - EXHIBIT 7
Page 65 - EXHIBIT 8
Subdocument 11 - EX-10.7 - EX-10.7
Page 1 - Exhibit 10.7
Subdocument 12 - EX-10.8 - EX-10.8
Page 1 - Exhibit 10.8
Page 2 - N/A
Page 3 - Exhibit 3 Development Plan **** ****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH T
Subdocument 13 - EX-10.9 - EX-10.9
Page 1 - Exhibit 10.9
Subdocument 14 - EX-10.10 - EX-10.10
Page 1 - Exhibit 10.10
Page 2 - TABLE OF CONTENTS
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - BACE RESEARCH COLLABORATION AND LICENSE AGREEMENT
Page 7 - in vitro
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - Handelsgesetzbuch
Page 12 - N/A
Page 13 - Handelsgesetzbuch
Page 14 - de jure
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - 2. LICENSE GRANTS, OWNERSHIP AND EXCLUSIVITY
Page 19 - Vitae s Right to Sublicense and Subcontract
Page 20 - 3. GOVERNANCE
Page 21 - Meetings
Page 22 - Joint Research Committee
Page 23 - Decision-Making
Page 24 - Meetings
Page 25 - Expenses
Page 26 - Vitae s Responsibilities
Page 27 - Reports
Page 28 - Development Candidate Selection
Page 29 - Minimum Diligence
Page 30 - pro rata
Page 31 - Reports
Page 32 - Recalls or Corrective Action
Page 33 - Execution Payment
Page 34 - Development Milestones
Page 35 - Commercialization Milestones
Page 36 - bona fide
Page 37 - Royalty Adjustments
Page 38 - Multiple Royalties
Page 39 - Confidentiality
Page 40 - Remedies
Page 41 - BI Representations, Warranties and Covenants
Page 42 - Vitae Representations and Warranties
Page 43 - Disclaimer of Warranty
Page 44 - Indemnification by BI
Page 45 - Insurance
Page 46 - Prosecution and Maintenance of Patents
Page 47 - Selection of Patent Counsel
Page 48 - BI s Step-In Rights
Page 49 - Supplementary Protection Certificates
Page 50 - Infringement of Patents
Page 51 - Assistance
Page 52 - Termination for Material Breach
Page 53 - Other Termination Rights
Page 54 - Terminations Other Than Material Breach by Vitae
Page 55 - Change of Control
Page 56 - Accrued Rights; Surviving Obligations
Page 57 - Publications
Page 58 - Public Announcements
Page 59 - Force Majeure
Page 60 - Attorneys Fees and Related Costs
Page 61 - Severability
Page 62 - Ambiguities
Page 63 - EXHIBIT 1
Page 64 - EXHIBIT 2
Page 65 - EXHIBIT 3
Page 66 - EXHIBIT 4
Page 67 - EXHIBIT 5
Page 68 - EXHIBIT 6
Page 69 - EXHIBIT 7
Page 70 - About BACE Inhibition
Page 71 - About Boehringer Ingelheim
Page 72 - EXHIBIT 9
Page 73 - **** ****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
Subdocument 15 - EX-10.11 - EX-10.11
Page 1 - Exhibit 10.11
Subdocument 16 - EX-10.12 - EX-10.12
Page 1 - Exhibit 10.12
Page 2 - [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK. SIGNATURES FOLLOW.]
Page 3 - IN WITNESS WHEREOF, Vitae and BI, by their duly authorized officers, have executed this Amendment as
Subdocument 17 - EX-10.13 - EX-10.13
Page 1 - Exhibit 10.13
Page 2 - IN WITNESS WHEREOF, Vitae and BI, by their duly authorized officers, have executed this Amendment as
Subdocument 18 - EX-10.14 - EX-10.14
Page 1 - Exhibit 10.14
Page 2 - N/A
Page 3 - Stock options granted hereunder will have a Change in Control provision which shall stipulate that i
Subdocument 19 - EX-10.15 - EX-10.15
Page 1 - Exhibit 10.15
Page 2 - This letter agreement may be executed in two counterparts, each of which will be deemed an original,
Subdocument 20 - EX-10.16 - EX-10.16
Page 1 - Exhibit 10.16
Subdocument 21 - EX-10.17 - EX-10.17
Page 1 - Exhibit 10.17
Page 2 - N/A
Page 3 - This letter constitutes our entire offer regarding the terms and conditions of your prospective empl
Subdocument 22 - EX-10.18 - EX-10.18
Page 1 - Exhibit 10.18
Page 2 - This letter agreement may be executed in two counterparts, each of which will be deemed an original,
Subdocument 23 - EX-10.19 - EX-10.19
Page 1 - Exhibit 10.19
Page 2 - Termination Benefits
Page 3 - Background Check
Page 4 - Very truly yours, VITAE PHARMACEUTICALS, INC.
Subdocument 24 - EX-10.20 - EX-10.20
Page 1 - Exhibit 10.20
Page 2 - Mandatory Deferral of Payments.
Subdocument 25 - EX-10.21 - EX-10.21
Page 1 - Exhibit 10.21
Page 2 - Severance:
Page 3 - Separation from Service:
Page 4 - I have read and accept the terms of this employment offer:
Subdocument 26 - EX-10.22 - EX-10.22
Page 1 - Exhibit 10.22
Page 2 - Severance:
Page 3 - Corporate Transaction
Page 4 - Entire Agreement:
Subdocument 27 - EX-10.23 - EX-10.23
Page 1 - Exhibit 10.23
Page 2 - N/A
Page 3 - Nothing in this letter agreement or the stock option agreement should be construed to interfere with
Subdocument 28 - EX-10.24 - EX-10.24
Page 1 - Exhibit 10.24
Page 2 - Permitted Prepayment of Term Loan
Page 3 - 2.4 Fees.
Page 4 - 3.2 Conditions Precedent to all Credit Extensions.
Page 5 - 4 CREATION OF SECURITY INTEREST
Page 6 - 5.7 Subsidiaries; Investments.
Page 7 - 6.1 Government Compliance.
Page 8 - 6.4 Taxes; Pensions.
Page 9 - 6.7 Protection of Intellectual Property Rights.
Page 10 - N/A
Page 11 - Event of Default
Page 12 - N/A
Page 13 - N/A
Page 14 - Communication
Page 15 - TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, BORROWER, LENDERS AND COLLATERAL AGENT EACH WAIVE
Page 16 - N/A
Page 17 - N/A
Page 18 - Account
Page 19 - Borrower s Books
Page 20 - Commodity Account
Page 21 - Equipment
Page 22 - Loan Payment/Advance Request Form
Page 23 - Permitted Investments
Page 24 - but
Page 25 - Requirement of Law
Page 26 - EXHIBIT A
Page 27 - EXHIBIT B
Page 28 - BORROWER:
Page 29 - EXHIBIT C -COMPLIANCE CERTIFICATE
Page 30 - N/A
Page 31 - EXHIBIT D
Page 32 - N/A
Page 33 - EXHIBIT E
Subdocument 29 - EX-10.25 - EX-10.25
Page 1 - Exhibit 10.25
Page 2 - Trading Market
Page 3 - Cash/Public Acquisition
Page 4 - ADJUSTMENTS TO THE SHARES AND WARRANT PRICE
Page 5 - Notice/Certificate as to Adjustments
Page 6 - REPRESENTATIONS, WARRANTIES OF THE HOLDER
Page 7 - Accredited Investor Status
Page 8 - Compliance with Securities Laws on Transfer
Page 9 - Waiver
Page 10 - N/A
Page 11 - NOTICE OF EXERCISE
Subdocument 30 - EX-10.26 - EX-10.26
Page 1 - Exhibit 10.26
Page 2 - Trading Market
Page 3 - Cash/Public Acquisition
Page 4 - ADJUSTMENTS TO THE SHARES AND WARRANT PRICE
Page 5 - Notice/Certificate as to Adjustments
Page 6 - REPRESENTATIONS
Page 7 - Compliance with Securities Laws on Transfer
Page 8 - Waiver
Page 9 - N/A
Page 10 - NOTICE OF EXERCISE
Page 11 - APPENDIX 2
Subdocument 31 - EX-10.27 - EX-10.27
Page 1 - Exhibit 10.27
Page 2 - Trading Market
Page 3 - Cash/Public Acquisition
Page 4 - ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.
Page 5 - Notice/Certificate as to Adjustments.
Page 6 - REPRESENTATIONS, WARRANTIES OF THE HOLDER.
Page 7 - Compliance with Securities Laws on Transfer.
Page 8 - Waiver.
Page 9 - N/A
Page 10 - NOTICE OF EXERCISE
Page 11 - APPENDIX 2
Subdocument 32 - EX-10.28 - EX-10.28
Page 1 - Exhibit 10.28
Page 2 - AGREEMENT OF LEASE
Page 3 - Term
Page 4 - Notice Addr
Page 5 - Liquidated Damages Security :
Page 6 - Permitted Uses :
Page 7 - (a)
Page 8 - (iii)
Page 9 - Rent
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - CONFESSION OF JUDGMENT FOR POSSESSION.
Page 16 - N/A
Page 17 - Additional Notice
Page 18 - N/A
Page 19 - Environmental Statutes
Page 20 - 21. SUBORDINATION.
Page 21 - 24. WAIVER OF SUBROGATION.
Page 22 - 26. SECURITY INTEREST.
Page 23 - 29. QUIET ENJOYMENT.
Page 24 - Force Majeure
Page 25 - 32. EXPANSION OPTION.
Page 26 - LANDLORD SHALL ARISE UNTIL THIS INSTRUMENT IS SIGNED BY BOTH LANDLORD AND TENANT.
Page 27 - IN WITNESS WHEREOF,
Page 28 - N/A
Page 29 - EXHIBIT B
Page 30 - N/A
Page 31 - EXHIBIT C
Page 32 - EXHIBIT D
Page 33 - N/A
Page 34 - EXHIBIT E
Page 35 - EXHIBIT F
Page 36 - MEMORANDUM OF LEASE
Page 37 - Right of First Refusal to Purchase
Page 38 - N/A
Page 39 - Miscellaneous
Page 40 - N/A
Page 41 - N/A
Page 42 - EXHIBIT A
Page 43 - N/A
Page 44 - EXHIBIT B
Page 45 - N/A
Page 46 - FIRST AMENDMENT TO LEASE AGREEMENT
Page 47 - N/A
Page 48 - IN WITNESS WHEREOF, the parties hereto, intending to be legally bound hereby, have executed this Fir
Subdocument 33 - EX-23.1 - EX-23.1
Page 1 - Exhibit 23.1
Page 2 - N/A